Stock Region Penny Picks
Stock Region Penny Picks Watchlist Newsletter - Tuesday, July 29, 2025
Stock Region Penny Picks Watchlist Newsletter - Tuesday, July 29, 2025
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This newsletter is for informational purposes only and not financial advice. Always do your due diligence before making investment decisions.
Hello, Stock Region crew! Today’s lineup serves a buffet of industry-changing moves, clinical advancements, and daring strategies. Here’s what’s hot off the presses and worth your attention:
$BMNR – BitMine Immersion Eyes a Massive Stock Repurchase
Highlight: BMNR has rolled out a jaw-dropping $1 billion stock buyback program.
Commentary: A billion-dollar vote of confidence! This move might signal their belief in undervaluation or aim to consolidate ownership. Could this turbocharge the stock price? Definitely one to watch!
$CGTX – Cognition Therapeutics Wows at AAIC
Highlight: Data was unveiled showing Zervimesine’s (CT1812) potential in combating Dementia with Lewy Bodies and Alzheimer’s Disease.
Commentary: Neurological diseases touch millions, and a breakthrough here could be monumental. If CT1812 delivers, CGTX might be sitting at the center of the next health revolution.
$DRRX – DURECT Gets Picked Up by Bausch Health
Highlight: Acquisition alert! Bausch Health is boosting its liver disease portfolio by acquiring DURECT.
Commentary: Pharmaceuticals thrive on innovation, and snapping up dynamic players like DURECT always stirs curiosity. The liver health space might be heating up!
$ZOOZ – ZOOZ Goes Crypto-Centric with $180M Strategy
Highlight: Launching a Bitcoin Treasury Reserve strategy following a private placement deal of $180 million.
Commentary: Crypto fans, pay attention! ZOOZ is making moves to align with Bitcoin enthusiasts. A bold bet, but will it payoff in this volatile space?
$ATOS – Atossa Therapeutics Making Waves in Breast Cancer Research
Highlight: Positive FDA feedback on (Z)-Endoxifen clinical program for ER+/HER2- metastatic breast cancer.
Commentary: Breast cancer research is a high-stakes field, and every step towards better treatment options matters. ATOS may become a significant force for change—and investors may look to align with their mission.
$CLDI – Calidi Biotherapeutics Breaks New Ground in Cancer Therapy
Highlight: Their CLD-201 received FDA Fast Track designation, targeting soft tissue sarcoma.
Commentary: A first-in-class stem-cell based therapy? Wow. Regulatory momentum like this can propel a stock to new heights. Keep CLDI on your radar.
$NTHI – NeOnc Technologies Partners for $50M Expansion
Highlight: A strategic partnership with Quazar Investment secured $50 million.
Commentary: Partnerships like this can offer the lifeline or springboard smaller firms need to make a big impact. NTHI could become a surprise player in their sector.
$AEHL – AEHL Readies Bitcoin Play with $50M Deal
Highlight: A $50 million strategic financing agreement to deepen their foray into Bitcoin acquisition.
Commentary: Another Bitcoin story worth watching! With regulatory environments shifting for crypto, AEHL’s timing is bold and possibly risky—but that’s where the drama lies.
$ACRS – Aclaris Advances Immunology Therapy
Highlight: Phase 2a trial success for ATI-2138, a selective ITK and JAK3 inhibitor.
Commentary: This development could broaden therapeutic options for immune-related conditions. Achieving trial endpoints is no small feat, and Aclaris seems determined to transform their potential into reality.
$CRDF – Cardiff Oncology Shines in RAS-Mutated Cancer Trials
Highlight: Positive data from a Phase 2 trial targeting RAS-mutated metastatic colorectal cancer.
Commentary: Oncology breakthroughs are game-changers. Cardiff's dedication to innovation shows promise—and investors tend to notice.
$SILO – Silo Pharma Diversifies with New Assets
Highlight: Entered an agreement to acquire cutting-edge software and domain assets like “r2crypto.com.”
Commentary: An unexpected pivot. Silo Pharma seems to be hedging into the tech world. Is this diversification a genius move or a distraction? Time will tell.
With healthcare innovation and crypto strategies dominating today’s updates, volatility-lovers and long-term strategists alike have options to explore.
Stay informed and invest responsibly,
The Stock Region Team
Disclaimer: This newsletter does not constitute financial advice. Always consult a financial professional about investment risks.